Glaukos
Glaukos is an ophthalmic medical technology and pharmaceutical company pioneering micro-invasive glaucoma surgery (MIGS) and sustained-release drug delivery for glaucoma, keratoconus, and retinal diseases. It serves ophthalmologists across 17 countries via direct sales and reaches 30+ countries through distributors.
- Company typePublic
- Founded1998
- HeadquartersSan Clemente, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Glaukos does
Glaukos Corporation (NYSE: GKOS) is a publicly-traded ophthalmic medical technology and pharmaceutical company founded in 1998 and headquartered in Aliso Viejo, California. The company pioneered the micro-invasive glaucoma surgery (MIGS) category and now operates five proprietary technology platforms: (1) the iStent Micro-Surgical Device Platform (iStent, iStent inject W, iStent infinite, iAccess), (2) the iDose Sustained-Release Pharmaceutical Platform, (3) the iLution Transdermal Drug Delivery Platform, (4) the iLink Bio-Activated Pharmaceutical Platform (Epioxa, Photrexa, KXL System with riboflavin formulations), and (5) the Retina XR Bio-Erodible Platform. Core commercial products include the iStent trabecular micro-bypass stent family (over 3 million implants globally), iDose TR (FDA-approved travoprost intracameral implant for sustained IOP reduction), Epioxa (first FDA-approved epithelium-on, incision-free corneal cross-linking therapy for keratoconus, approved October 2025), Mitosol (ophthalmic mitomycin C), and the KXL System.
The company serves ophthalmic surgeons, eye care professionals, and ultimately patients with chronic eye diseases including open-angle glaucoma, ocular hypertension, progressive keratoconus, and (in development) retinal diseases such as AMD and DME. Revenue is generated through one-time device and pharmaceutical product sales via a direct sales organization covering 17 countries with more than 250 commercial sales personnel, supplemented by international distributor relationships reaching 30+ countries. Specialty pharmaceutical distribution (e.g., Epioxa) flows through a single-source specialty pharmacy partnership with Orsini Healthcare. FY2025 net sales reached $507.4 million (up 32% year-over-year), Q1 2026 net sales reached $150.6 million (up 41% year-over-year), and FY2026 guidance has been raised to $620–$635 million. The company reinvests approximately 35% of sales into R&D, has spent over $800 million cumulatively since 2018, and maintains a pipeline of 14+ candidates across the five platforms.
Glaukos firmographics
Firmographics- Name
- Glaukos
- Legal name
- Glaukos Corporation
- Website
- https://glaukos.com
- Company type
- Public
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Glaukos is an ophthalmic medical technology and pharmaceutical company pioneering micro-invasive glaucoma surgery (MIGS) and sustained-release drug delivery for glaucoma, keratoconus, and retinal diseases. It serves ophthalmologists across 17 countries via direct sales and reaches 30+ countries through distributors.
- Ownership category
- akta.pro rank
Glaukos industry classification
Industry- Product category
- Ophthalmic Medical Devices
- NAICS
- Ophthalmic Goods Manufacturing (339115), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851), Pharmaceutical Preparations (2834), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty) (HLAHAJAI)
- akta.pro secondary industries
- Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery) (HLAHAJAK), Vitreoretinal Surgical Devices (Vitrectomy Systems, Endolaser, Illumination, Tamponades) (HLAHAJAJ), Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL), Ophthalmology Pharmaceuticals (HLAIAAAL), Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
Keywords
Where Glaukos is headquartered
LocationHeadquarters
- HQ city
- San Clemente
- HQ country
- United States
- HQ region
- North America
Offices9 records
Markets served
Glaukos business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Medical Device Sales (iStent, iDose TR): Revenue from sale of micro-invasive glaucoma surgery devices and intracameral implants through direct sales force and distribution partners.
- Pharmaceutical Products (Epioxa): Revenue from FDA-approved corneal cross-linking therapy for keratoconus, commercialized in early 2026.
- Mitosol (Mitomycin C): FDA-approved antimetabolite for adjunctive use in glaucoma filtration surgery.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Epioxa J-code J2789 assigned for Medicare/Medicaid billing |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Glaukos product offering
Product offeringCore offering
Glaukos develops and commercializes novel ophthalmic therapies for chronic eye diseases, including micro-invasive glaucoma surgery (MIGS) devices (iStent family, iAccess), sustained-release intracameral pharmaceutical implants (iDose TR), bio-activated corneal cross-linking therapies (Epioxa, Photrexa, KXL System with riboflavin formulations), and bio-erodible sustained-release drug delivery platforms for retinal diseases. The company sells these products to ophthalmologists, hospitals, and ambulatory surgical centers globally.
Product overview
Glaukos is an ophthalmic medical technology and pharmaceutical company offering a unified portfolio of novel therapies for glaucoma, corneal disorders, and retinal diseases. The product portfolio is organized around five proprietary technology platforms: (1) iStent Micro-Surgical Device Platform (iStent, iStent inject W, iStent infinite, iAccess), (2) iDose Sustained-Release Pharmaceutical Platform (iDose TR, iDose TREX), (3) iLution Transdermal Platform (GLK-301, GLK-302, GLK-311, GLK-321), (4) iLink Bio-Activated Platform (Epioxa, Photrexa, KXL System), and (5) Retina XR Bio-Erodible Platform. The flagship products include iDose TR (travoprost intracameral implant) for glaucoma, iStent inject W family for MIGS procedures, Epioxa (FDA-approved epithelium-on cross-linking) for keratoconus, and the KXL System with riboflavin formulations for corneal cross-linking. The company also develops sustained-release drug delivery platforms for retinal diseases including AMD and DME.
Differentiator
Problem solved
Functional benefit
Brands
- iDose: Long-duration intracameral implant for IOP reduction in glaucoma patients
- iStent
- KXL System
- iLink
- Epioxa
- Mitosol
Products and services
- iDose TR (travoprost intracameral implant) 75 mcg First-of-its-kind, long-duration, anchored intracameral procedural pharmaceutical therapy for reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Delivers continuous prostaglandin analog therapy directly into the anterior chamber.
- iStent inject W with Infinite Injector Technology Gold standard micro-invasive glaucoma surgery (MIGS) device with next-generation injector system and precision-engineered stent design featuring wide flange at base. Indicated for use with cataract surgery in adult patients with mild to moderate primary open-angle glaucoma.
- iStent inject W Trabecular micro-bypass device indicated for use in conjunction with cataract surgery for reduction of intraocular pressure in adult patients with mild to moderate primary open-angle glaucoma. Creates two patent bypass pathways through the trabecular meshwork.
- iStent infinite First micro-invasive standalone implantable device for reduction of intraocular pressure in adult patients with primary open-angle glaucoma in whom previous medical and surgical treatment has failed. Features 3 anatomically designed stents preloaded into an elegant injector system.
- iAccess Precision Blade 30-gauge precision blade designed to open trabecular meshwork over an area greater than 90 degrees to directly access Schlemm's canal. Features titanium nitride-coated blade creating approximately 220-micrometer-diameter incisions with built-in safety backstop.
- Mitosol (mitomycin for solution) 0.2 mg/vial FDA-approved antimetabolite indicated as adjunct to ab-externo glaucoma surgery. The only FDA-approved ophthalmic Mitomycin C formulation with closed-system preparation and disposal meeting USP<800> standards.
- Epioxa (riboflavin 5'-phosphate ophthalmic solution) FDA-approved first and only incision-free, epithelium-on corneal cross-linking therapy for treatment of keratoconus. Consists of EPIOXA HD (0.239%) and EPIOXA (0.177%) used with O2n System and Boost Goggles.
- KXL System CE-marked system for performing corneal cross-linking and Lasik Xtra procedures. Features up to 45 mW/cm2 power output, wireless remote control, large touchscreen, and multiple preset treatment protocols.
- Riboflavin Formulations (VibeX Xtra, VibeX Rapid, ParaCel, MedioCROSS) Family of CE-marked riboflavin formulations for various cross-linking protocols including epithelium-off, trans-epithelial, and intra-stromal applications. Include VibeX Xtra for Lasik Xtra, VibeX Rapid for accelerated cross-linking, and ParaCel for epithelium-on procedures.
Quantifiable outcome
- Q1 2026 revenue of $150.6 million, up 41% year-over-year
- +5 more outcomes
Companies that use Glaukos
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles1 record
Glaukos technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Glaukos partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core, strategic and minor.
- Orsini HealthcarecoreOrsini serves as the single-source specialty pharmacy partner for Glaukos' FDA-approved Epioxa therapy for keratoconus. The partnership builds on over five years of collaboration to serve keratoconus patients, providing distribution, patient support, and reimbursement assistance services.
- Prevent BlindnessstrategicPrevent Blindness declared March 23-29, 2026 as first-ever Keratoconus Week, supported by Glaukos. The partnership aims to raise awareness about keratoconus and provide educational resources to patients and healthcare providers.
- J.P. Morgan Healthcare ConferenceminorGlaukos presented at the UBS Global Healthcare Conference 2025, participating in investor and analyst meetings to discuss company strategy, products, and pipeline.
- Celanese CorporationcorePartnership to launch iDose TR travoprost intracameral implant using Celanese's VitalDose drug-delivery platform for glaucoma treatment. This technology integration enables the sustained-release formulation of travoprost.
- iVeena Delivery SystemsminoriVeena Delivery Systems licensing agreement with Glaukos Corporation for drug delivery technology. The partnership was credited for prior milestones including financing rounds and regulatory submissions.
- Glaukos Charitable Foundation PartnersminorPartnership with over 158 humanitarian organizations including ORBIS, SEE International, Lions Club International, LDS Charities, Americares, and others. Donated over 9,000 IOP-lowering products/stents to underserved glaucoma patients in 62 countries.
Scale indicators17 records
Recent moves3 records
Glaukos competitors and assessment
Company assessmentDirect peers
- Ocular Therapeutix: Develops sustained-release ocular drug delivery platforms (e.g., DEXTENZA) targeting the same ophthalmic-surgeon channel as Glaukos's iDose TR, with strong overlap in intracameral and punctal drug-delivery technology.
- Alcon: Largest dedicated ophthalmic company globally, with MIGS-adjacent surgical devices, cataract/IOL bundles, and an emerging pharma franchise overlapping with Glaukos's glaucoma and corneal health lines. Directly competes for surgeon mindshare and MIGS procedure volume.
- Bausch + Lomb: Spun-off from Bausch Health, Bausch + Lomb competes head-to-head across ophthalmic pharmaceuticals (e.g., Vyzulta), surgical devices, and MIGS categories, and is the closest diversified competitor to Glaukos's combined device + specialty pharma model.
- Sight Sciences: Pure-play MIGS competitor with the OMNI Surgical System for canal-based glaucoma surgery, directly overlapping with Glaukos's iStent family for the same interventional glaucoma call point.
- Santen Pharmaceutical: Japan-headquartered global ophthalmic specialty pharmaceutical company with leading glaucoma and corneal franchises (e.g., Tapros, Diquas) and a direct sales channel that overlaps with Glaukos's international, including Japan, presence.
Emerging players
- Novaliq: Focuses on novel ocular surface and dry-eye pharmaceuticals (e.g., NOV03, CyclASol) with overlap on Glaukos's iLution platform candidates (GLK-301 dry eye, GLK-302 presbyopia), competing for the same ocular-surface prescriber.
- Nicox Ophthalmics: European-listed ophthalmic specialty pharma focused on glaucoma (NCX-470) and ocular surface diseases, comparable in scale and stage to Glaukos's corneal health and iDose follow-on programs.
- Apellis Pharmaceuticals: Markets Syfovre/Empaveli with growing ophthalmic retina presence (geographic atrophy), adjacent to Glaukos's Retina XR sustained-release platform targeting AMD/DME; competes for retina specialists and physician relationships.
Others
- iVeena Delivery Systems: Drug-delivery technology licensor and stated Glaukos partner for ocular drug-delivery formulations; comparable as an enabling technology platform in the ocular drug-delivery space that Glaukos commercializes against.
Broad incumbents
- AbbVie (Allergan): Owns the Durysta bimatoprost intracameral implant — Glaukos's most direct intracameral competitor — and a broad ophthalmic pharma portfolio (Lumigan, Alphagan, etc.) via legacy Allergan Aesthetics, plus a much larger capital base.
Market position
Strengths5 records
Weaknesses5 records
Key risks6 records
Key highlights6 records
Customer concentration
Glaukos social profiles
Digital presenceGlaukos financial estimates
Financial estimateRevenue estimate
Valuation estimate
Glaukos leadership team
Management profileNumber of profiles
Profiles4 records
Glaukos subsidiaries and ownership
Company hierarchySubsidiaries3 records
Glaukos funding detail
Funding detailFunding overview
Funding rounds7 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Glaukos M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Glaukos
What does Glaukos do?
Glaukos develops and commercializes novel ophthalmic therapies for chronic eye diseases, including micro-invasive glaucoma surgery (MIGS) devices (iStent family, iAccess), sustained-release intracameral pharmaceutical implants (iDose TR), bio-activated corneal cross-linking therapies (Epioxa, Photrexa, KXL System with riboflavin formulations), and bio-erodible sustained-release drug delivery platforms for retinal diseases. The company sells these products to ophthalmologists, hospitals, and ambulatory surgical centers globally.
Is Glaukos a public or private company?
Glaukos is a public company. It is classified as public and is currently operating.
When was Glaukos founded?
Glaukos was founded in 1998. It employs 1,001 to 5,000 people.
Where is Glaukos based?
Glaukos is headquartered in San Clemente, United States, in the North America region.
How does Glaukos make money?
Three revenue lines are on record. Medical Device Sales (iStent, iDose TR) is the primary driver. The others are pharmaceutical Products (Epioxa) and mitosol (Mitomycin C).
Who are Glaukos's main competitors?
Direct peers on record are Ocular Therapeutix, Alcon, Bausch + Lomb, Sight Sciences and Santen Pharmaceutical. Emerging players are Novaliq, Nicox Ophthalmics and Apellis Pharmaceuticals. iVeena Delivery Systems is listed as an others. AbbVie (Allergan) is listed as a broad incumbent.
Does Glaukos have an API?
No public API is recorded for Glaukos.
What industry is Glaukos in?
Glaukos's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAI, Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty), with a secondary code of HLAHAJAK, Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery). Its NAICS code is 339115 and its SIC code is 3841.